201 related articles for article (PubMed ID: 27188289)
1. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.
Önenli Mungan N; Yıldızdaş D; Kör D; Horoz ÖÖ; İncecik F; Öktem M; Sander J
Metab Brain Dis; 2016 Oct; 31(5):1181-3. PubMed ID: 27188289
[TBL] [Abstract][Full Text] [Related]
2. A Case Report of a Very Rare Association of Tyrosinemia type I and Pancreatitis Mimicking Neurologic Crisis of Tyrosinemia Type I.
Uçar HK; Tümgör G; Kör D; Kardaş F; Mungan NÖ
Balkan Med J; 2016 May; 33(3):370-2. PubMed ID: 27308087
[TBL] [Abstract][Full Text] [Related]
3. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
4. Tyrosinemia type I: Case series with response to treatment to NTBC.
Shah I; Shah F
Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
[TBL] [Abstract][Full Text] [Related]
5. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
7. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.
Schlump JU; Perot C; Ketteler K; Schiff M; Mayatepek E; Wendel U; Spiekerkoetter U
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S223-5. PubMed ID: 18500574
[TBL] [Abstract][Full Text] [Related]
8. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
9. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
[No Abstract] [Full Text] [Related]
10. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
11. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
12. Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended.
D'Eufemia P; Celli M; Tetti M; Finocchiaro R
Eur J Pediatr; 2011 Jun; 170(6):819. PubMed ID: 21340489
[No Abstract] [Full Text] [Related]
13. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
[No Abstract] [Full Text] [Related]
14. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
15. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
16. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
17. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
18. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
20. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]